Copenhagen, Denmark - 28 August 2026 - Cessatech A/S ("Cessatech" or the "Company"), a late-stage paediatric specialty company developing and commercializing hospital medicines for children, today announced the interim report for the second quarter of 2026, together with an update on key developments after the reporting period. The report is available on Cessatech's website.

Second quarter financial results 2026 (1 April - 30 June)

• Net revenue was KDKK 0
• Operating result was KDKK -3.469
• Net result was KDKK -2.773
• Cash at bank end of the period was KDKK 2.348
• Earnings per share* was DKK -0,15
• Solidity** was 77%

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 June 2026 amounted to 18.576.437 shares, the average number of shares during the second quarter was 18.576.437  
**Solidity: Total equity divided by total capital and liability

The Interim Report has not been reviewed by the Company's auditor.

Jes Trygved, CEO at Cessatech said:
"During the second quarter, we continued to advance Cessatech's strategy while expanding our paediatric portfolio with CT004, a new programme developed in collaboration with Rigshospitalet. Following the quarter, we reached an important commercial milestone with the release of the first commercial batch of CT001 in the U.S., enabling launch activities with selected hospitals to begin. In Europe, while we were disappointed by the CHMP opinion on KemSu/CT001, we remain confident in the overall benefit-risk profile and, together with Proveca, are pursuing the established re-examination process. With CT001 now entering its commercial phase in the U.S. and CT004 broadening our pipeline, we believe Cessatech is well positioned for the next stage of its development."